Cold agglutinin disease (CAD) is a rare type of autoimmune hemolytic anemia in which your immune system produces antibodies that attack and destroy your own red blood cells, particularly when your body temperature drops. It affects roughly 12 to 16 people per million, with about 1 new case per million diagnosed each year in Northern Europe, and those numbers are likely slight underestimates. The disease ranges from a mild laboratory finding with few symptoms to a chronic, debilitating condition with severe anemia and painful circulation problems.
How Cold Agglutinin Disease Works
The core problem in CAD is an antibody called IgM that your body produces by mistake. These IgM antibodies latch onto a specific marker (the I antigen) on the surface of your red blood cells when temperatures dip below normal body temperature. This binding causes red blood cells to clump together, a process called agglutination.
Once IgM binds to a red blood cell, it triggers a chain reaction in the complement system, one of your body’s immune defense pathways. The IgM-red blood cell complex activates a series of proteins that essentially tag the cell for destruction. Most of this destruction happens in the liver, where immune cells recognize the tagged red blood cells and break them down. This is called extravascular hemolysis, and it’s responsible for the bulk of the anemia in CAD. A small amount of red blood cell destruction also happens directly in the bloodstream, though your body has built-in safeguards that limit this.
What makes the disease so variable from person to person is something called thermal amplitude: the highest temperature at which the antibodies still bind to red blood cells. If your antibodies only react near freezing temperatures, you may have minimal symptoms. But if they react at temperatures closer to normal body temperature, even the mild cooling that happens in your fingers, toes, nose, and ears during everyday life can trigger ongoing red blood cell destruction. The severity of anemia depends more on this thermal amplitude than on how many antibodies are circulating in your blood.
Primary vs. Secondary Forms
CAD comes in two forms. Primary CAD has no obvious external trigger and is considered a type of low-grade bone marrow disorder. The bone marrow produces a clone of abnormal cells that churn out the problematic IgM antibodies. This form is chronic and most commonly appears in adults in their 60s and 70s.
Secondary cold agglutinin syndrome is triggered by something else, most often an infection or a blood cancer. The most well-known infectious triggers are Mycoplasma pneumoniae (a common cause of “walking pneumonia”) and Epstein-Barr virus (the virus behind infectious mononucleosis). Other reported triggers include hepatitis A, malaria, HIV, cytomegalovirus, rubella, influenza, and certain bacterial infections like Klebsiella. The infection-related form is usually temporary and resolves once the underlying infection clears. Secondary cases linked to blood cancers such as chronic lymphocytic leukemia or Waldenström’s macroglobulinemia tend to follow the course of the underlying malignancy.
Symptoms and What They Feel Like
The hallmark symptoms of CAD fall into two categories: anemia-related symptoms and cold-triggered circulation problems.
Anemia from ongoing red blood cell destruction causes chronic fatigue, paleness, shortness of breath, and general weakness. The anemia can be mild, moderate, or severe depending on how aggressively the antibodies are destroying red blood cells. Some people experience dark-colored urine after prolonged cold exposure, which signals that hemoglobin from destroyed red blood cells is being filtered through the kidneys, though this is uncommon.
Cold-triggered circulation symptoms affect roughly 90% of patients. The most characteristic is acrocyanosis, a purplish-blue discoloration of the ears, nose tip, forehead, and fingers that appears during or shortly after cold exposure. About 44% of patients in one large study reported acrocyanosis as their most common symptom. A mottled, net-like skin pattern called livedo reticularis can also appear. In rare and severe cases, restricted blood flow can cause tissue damage and pain in the extremities, though actual skin ulceration is uncommon.
It’s worth noting that the circulatory symptoms in CAD look different from Raynaud’s phenomenon, even though they’re sometimes confused. Raynaud’s causes a distinctive three-phase color change (white, then blue, then red) driven by blood vessel spasms. In CAD, the discoloration comes from red blood cells clumping in cooled blood vessels, not from vasospasm, so the triphasic pattern doesn’t occur.
How It’s Diagnosed
Diagnosing CAD requires a combination of blood tests that confirm both the anemia and the presence of the offending antibodies. The key criteria include evidence of hemolytic anemia (your red blood cells are being destroyed faster than normal), a positive direct antiglobulin test showing complement proteins (specifically C3d) coating your red blood cells, and a cold agglutinin titer of 1:64 or higher measured at 4°C. Some older diagnostic frameworks set the threshold higher, at 1:256.
The direct antiglobulin test in CAD typically shows C3d positivity with a negative IgG result, which helps distinguish it from warm autoimmune hemolytic anemia, where IgG antibodies are the culprit. Monoclonal cold agglutinins, the type seen in primary CAD, tend to have higher titers and cause more significant red blood cell destruction than the polyclonal antibodies seen in infection-triggered cases. Doctors also assess the thermal amplitude when possible, since this predicts disease severity better than the antibody concentration alone.
Thrombosis Risk
One underappreciated danger of CAD is an increased risk of blood clots. A 10-year analysis found that people with CAD had roughly twice the overall risk of blood clots compared to matched individuals without the disease. The risk was especially pronounced for venous clots: 14.6% of CAD patients experienced a venous clotting event compared to 5.2% of people without CAD, translating to about a threefold increase in risk. Arterial clotting events occurred in 7.6% of CAD patients versus 3.7% of controls. This elevated risk is thought to stem from the chronic complement activation and ongoing red blood cell destruction that define the disease.
Treatment Options
The simplest and most important intervention is cold avoidance. Keeping warm, especially protecting the hands, feet, ears, and nose, can reduce the rate of red blood cell destruction by preventing the antibodies from binding in the first place. For some people with mild disease, this is enough.
When anemia is significant enough to require treatment, rituximab has been the standard first-line therapy for years. In a study of 16 patients treated with rituximab alone, the overall response rate was 62.5%, with 56% achieving complete remission. The median duration of response was about 24 months, meaning many patients eventually relapse and may need retreatment.
A major advance came in February 2022, when the FDA approved sutimlimab, the first drug specifically designed for CAD. Rather than targeting the antibody-producing cells, sutimlimab works by blocking an early step in the complement cascade, essentially preventing the immune system from tagging red blood cells for destruction even though the IgM antibodies are still present. It’s given as an intravenous infusion, weekly for the first two doses and then every two weeks. Dosing is weight-based: 6.5 grams for people weighing 39 to 74 kg and 7.5 grams for those 75 kg and above.
In clinical trials, sutimlimab produced meaningful improvements in hemoglobin levels without the need for transfusions. In the CARDINAL study of patients who had recently needed transfusions, 54% met the primary endpoint of normalized or substantially improved hemoglobin. The CADENZA trial, which enrolled patients who hadn’t needed recent transfusions, showed even stronger results: 73% of patients on sutimlimab met the primary endpoint compared to just 15% on placebo. Traditional treatments like splenectomy and corticosteroids, which are effective in warm autoimmune hemolytic anemia, generally do not work well for CAD because the red blood cell destruction primarily happens in the liver rather than the spleen, and the antibody production isn’t typically steroid-responsive.
Living With Cold Agglutinin Disease
For people with primary CAD, the disease is chronic but manageable for most. The severity fluctuates with seasons, infections, and cold exposure. Winter months and cold climates pose the greatest challenge, and some patients find that relocating to warmer regions or making significant lifestyle adjustments around temperature control meaningfully reduces their symptoms. Surgical procedures require special precautions to keep core body temperature above the reactive thermal amplitude of the antibody, preventing a hemolytic crisis under anesthesia.
Weight loss and enlarged lymph nodes can occur and sometimes signal progression of the underlying bone marrow disorder or, rarely, transformation to a more aggressive blood cancer. The elevated clotting risk means that unexplained leg swelling, chest pain, or sudden shortness of breath should be evaluated promptly. With appropriate monitoring and the expanding treatment options now available, most people with primary CAD maintain a reasonable quality of life, though the chronic fatigue and cold sensitivity remain ongoing challenges for many.